Skip to main content
SpringerLink
Log in

Therapy of pulmonary arterial hypertension in systemic sclerosis: An update

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Pulmonary arterial hypertension (PAH) affects 10% to 15% of patients with systemic sclerosis and is a major cause for disease-related morbidity and mortality. Over the past decade, significant progress has been made in the understanding of the pathophysiologic mechanisms underlying PAH. This progress led to the development of several new treatment options and, as a result, dramatically improved survival among this severely affected cohort. The outcome in patients with scleroderma-related PAH is much worse than that in patients with idiopathic PAH, and unfortunately only a few studies have assessed treatment and outcome among patients suffering from connective tissue disease-related PAH. In recent years, publications of connective tissue disease subgroup analysis from large trials in PAH have emerged. We review the current treatment options for PAH and the evidence for their use in scleroderma-related PAH.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Mukerjee D, St George D, Coleiro B, et al.: Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003, 62:1088–1093.

    Article  PubMed  CAS  Google Scholar 

  2. Hachulla E, Gressin V, Guillevin L, et al.: Pulmonary arterial hypertension in systemic sclerosis: definition of a screening algorithm for early detection (the ItinerAIR-Sclerodermie Study). Rev Med Interne 2004, 25:340–347.

    Article  PubMed  CAS  Google Scholar 

  3. Wigley FM, Lima JA, Mayes M, et al.: The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum 2005, 52:2125–2132.

    Article  PubMed  Google Scholar 

  4. Humbert M, Morrell NW, Archer SL, et al.: Cellular and molecular pathobiology of pulmonary arterial hypertension [review]. J Am Coll Cardiol 2004, 43(12 Suppl S):13S–24S.

    Article  PubMed  CAS  Google Scholar 

  5. Barst RJ, Rubin LJ, Long WA, et al.: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996, 334:296–302.

    Article  PubMed  CAS  Google Scholar 

  6. Badesch DB, Tapson VF, McGoon MD, et al.: Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000, 132:425–434.

    PubMed  CAS  Google Scholar 

  7. McLaughlin VV, Shillington A, Rich S: Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002, 106:1477–1482.

    Article  PubMed  CAS  Google Scholar 

  8. McLaughlin VV, Gaine SP, Barst RJ, et al.: Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 2003, 41:293–299.

    Article  PubMed  CAS  Google Scholar 

  9. Simonneau G, Barst RJ, Galie N, et al.: Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002, 165:800–804.

    PubMed  Google Scholar 

  10. Oudiz RJ, Schilz RJ, Barst RJ, et al.: Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 2004, 126:420–427.

    Article  PubMed  CAS  Google Scholar 

  11. Lang I, Gomez-Sanchez M, Kneussl M, et al.: Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest 2006, 129:1636–1643.

    Article  PubMed  CAS  Google Scholar 

  12. Voswinckel R, Enke B, Reichenberger F, et al.: Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. J Am Coll Cardiol 2006, 48:1672–1681.

    Article  PubMed  CAS  Google Scholar 

  13. Olschewski H, Simonneau G, Galie N, et al.: Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002, 347:322–329.

    Article  PubMed  CAS  Google Scholar 

  14. Barst RJ, McGoon M, McLaughlin V, et al.: Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003, 41:2119–2125.

    Article  PubMed  CAS  Google Scholar 

  15. Galie N, Humbert M, Vachiery JL, et al.: Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002, 39:1496–1502.

    Article  PubMed  CAS  Google Scholar 

  16. Galie N, Manes A, Branzi A: The endothelin system in pulmonary arterial hypertension [review]. Cardiovasc Res 2004, 61:227–237.

    Article  PubMed  CAS  Google Scholar 

  17. Rubens C, Ewert R, Halank M, et al.: Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 2001, 120:1562–1569.

    Article  PubMed  CAS  Google Scholar 

  18. Sticherling M: The role of endothelin in connective tissue diseases. Rheumatology (Oxford) 2006, 45(Suppl 3):iii8–iii10.

    Article  CAS  Google Scholar 

  19. Channick RN, Simonneau G, Sitbon O, et al.: Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001, 358:1119–1123.

    Article  PubMed  CAS  Google Scholar 

  20. Sitbon O, Badesch DB, Channick RN, et al.: Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003, 124:247–254.

    Article  PubMed  CAS  Google Scholar 

  21. Rubin LJ, Badesch DB, Barst RJ, et al.: Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002, 346:896–903.

    Article  PubMed  CAS  Google Scholar 

  22. Denton CP, Humbert M, Rubin L, Black CM: Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006, 65:1336–1340.

    Article  PubMed  CAS  Google Scholar 

  23. Williams MH, Das C, Handler CE, et al.: Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 2006, 92:926–932.

    Article  PubMed  CAS  Google Scholar 

  24. Hirata Y, Emori T, Eguchi S, et al.: Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest 1993, 91:1367–1373.

    Article  PubMed  CAS  Google Scholar 

  25. Dupuis J, Goresky CA, Fournier A: Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors. J Appl Physiol 1996, 81:1510–1515.

    PubMed  CAS  Google Scholar 

  26. Barst RJ, Langleben D, Frost A, et al.: Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004, 169:441–447.

    Article  PubMed  Google Scholar 

  27. Langleben D, Brock T, Dixon R, et al.: STRIDE 1: Effects of the selective ETA receptor antagonist, sitaxsentan sodium, in a patient population with pulmonary arterial hypertension that meets traditional inclusion criteria of previous pulmonary arterial hypertension trials. J Cardiovasc Pharmacol 2004, 44:S80–S84.

    Article  PubMed  CAS  Google Scholar 

  28. Barst RJ, Langleben D, Badesch D, et al.: Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006, 47:2049–2056.

    Article  PubMed  CAS  Google Scholar 

  29. Galie N, Ghofrani HA, Torbicki A, et al.: Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005, 353:2148–2157.

    Article  PubMed  CAS  Google Scholar 

  30. Badesch D, Burgess G, Parpia T, Rubin L: Sildenafil improves exercise ability and hemodynamics in patients with pulmonary arterial hypertension associated with connective tissue disease [abstract 693]. Presented at the American College of Rheumatology 70th Annual Scientific Meeting. San Diego, CA, USA; November 12–17, 2005.

  31. Wilkins MR, Paul GA, Strange JW, et al.: Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med 2005, 171:1292–1297.

    Article  PubMed  Google Scholar 

  32. Humbert M, Barst RJ, Robbins IM, et al.: Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004, 24:353–359.

    Article  PubMed  CAS  Google Scholar 

  33. McLaughlin VV, Oudiz RJ, Frost A, et al.: Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006, 174:1257–1263.

    Article  PubMed  CAS  Google Scholar 

  34. Wilkens H, Guth A, Konig J, et al.: Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001, 104:1218–1222.

    PubMed  CAS  Google Scholar 

  35. Ghofrani HA, Wiedemann R, Rose F, et al.: Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002, 136:515–522.

    PubMed  CAS  Google Scholar 

  36. Hoeper MM, Faulenbach C, Golpon H, et al.: Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 2004, 24:1007–1010.

    Article  PubMed  CAS  Google Scholar 

  37. Hoeper MM, Markevych I, Spiekerkoetter E, et al.: Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005, 26:858–863.

    Article  PubMed  CAS  Google Scholar 

  38. Badesch DB, Abman SH, Ahearn GS, et al.: Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004, 126(1 Suppl):35S–62S.

    Article  PubMed  Google Scholar 

  39. Galie N, Torbicki A, Barst R, et al.: Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004, 25:2243–2278.

    Article  PubMed  Google Scholar 

  40. Sanchez O, Sitbon O, Jais X, et al.: Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 2006, 130:182–189.

    Article  PubMed  CAS  Google Scholar 

  41. Kawut SM, Taichman DB, Archer-Chicko CL, et al.: Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003, 123:344–350.

    Article  PubMed  Google Scholar 

  42. MacGregor AJ, Canavan R, Knight C, et al.: Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) 2001, 40:453–459.

    Article  CAS  Google Scholar 

  43. Mukerjee D, St George D, Knight C, et al.: Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford) 2004, 43:461–466.

    Article  CAS  Google Scholar 

  44. McGoon M, Gutterman D, Steen V, et al.: Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004, 126(1 Suppl):14S–34S.

    Article  PubMed  Google Scholar 

  45. Mukerjee D, Yap LB, Holmes AM, et al.: Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. Respir Med 2003, 97:1230–1236.

    Article  PubMed  CAS  Google Scholar 

  46. Williams MH, Handler CE, Akram R, et al.: Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 2006, 27:1485–1494.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre for Rheumatology, Royal Free Hospital, Pond Street, London, UK, NW3 2QG

    Christopher P. Denton PhD, FRCP

Authors
  1. Christopher P. Denton PhD, FRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Svetlana I. Nihtyanova MBBS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher P. Denton PhD, FRCP.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Denton, C.P., Nihtyanova, S.I. Therapy of pulmonary arterial hypertension in systemic sclerosis: An update. Curr Rheumatol Rep 9, 158–164 (2007). https://doi.org/10.1007/s11926-007-0011-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-007-0011-4

Keywords

Search

Navigation